<DOC>
	<DOCNO>NCT01453218</DOCNO>
	<brief_summary>Renal dysfunction context liver transplantation major issue , difficult patient ' management determining worsen prognosis . Physiopathologically pretransplant renal dysfunction dependent multifactorial cause , include hypoperfusion-derived functional renal insufficiency , hepatorenal syndrome interstitial parenchymatous insufficiency . On top , intra- post-transplant event , include hypoperfusion calcineurin inhibitor nephrotoxicity may aggravate situation . At present MELD criterion favour allocation organs patient suffer renal insufficiency , least 30 % investigator liver transplant patient suffer degree renal impairment pretransplant . After liver transplant impair renal function tend recover partially completely , unless advanced parenchymatous lesion significantly involve major cause renal dysfunction . In context , calcineurin inhibitor avoid spar protocol may help recovery renal insufficiency , improve long-term prognosis . The use anti-CD25 antibody good option , provide limited antirejection prophylaxis , limit use antibody reduce cohort liver transplant patient . Polyclonal antibody might provide advantage management liver transplant patient renal insufficiency , without increase acute rejection episode allograft efficacy security evaluation low nephrotoxicity immunosuppression , base use ATeGe , liver transplant candidate pre-transplant renal dysfunction . The aim study evaluate efficacy security use immunosuppression base ATeGe liver transplant recipients pre-transplant renal dysfunction .</brief_summary>
	<brief_title>Safety Use ATeGe Liver Transplant Recipients With Pre-transplant Renal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<criteria>Patients moderate pretransplant renal dysfunction define serum creatinine level higher 1.5 mg/dl eGFR ( MDRD4 ) &lt; 60ml/min . First liver transplant , include split liver transplant . Patients aged 1870 year Without prior contraindication protocol biopsy allograft . Multiorgan transplantation and/or liver transplant DCD and/or ABO incompatibility . Uncontrolled concomitant infection ( include HIV seropositivity ) and/or diarrhoea , vomit active gastric ulcer . Fulminant hepatic insufficiency first indication liver transplant Hemodynamic instability prior liver transplant . Recipient present present previous neoplasia , except nonmetastatic basal squamous cutaneous carcinoma localize hepatocarcinoma diameter &lt; 5 cm &lt; 3 know lesion diameter &lt; 3 cm . Intolerance study medication . Patients receive vaccination attenuate living vaccine within previous 4 week . Severe leukopenia ( &lt; 1.2 X 10E9/L ) and/or thrombocytopenia ( &lt; 50x10E9/L ) and/or lymphocyte count ( CD2+/CD3+ ) less 10 cells/Âµl . Significant comorbidity . Breastfeeding female patient fertile age without negative pregnancy test accepting use reliable fertility control method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Renal insufficiency</keyword>
	<keyword>Liver transplant</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>Infections</keyword>
	<keyword>Hepatitis C recurrence</keyword>
</DOC>